The edge of lesion (2025)

Little, E., Baker, T., Peverill, J. et al.

Abstract

At AstraZeneca we utilise a wide variety of flank tumour models in rodents to gather data on the effectiveness of our Oncology drugs. During these studies tumour condition is closely monitored for appearance of lesions; typically a change of shape or appearance of the tumours, including scabs, holes or areas of necrosis; that will lead to humane endpoints as outlined by specific criteria in the project licence (PPL) (Figure 1). However we identified an opportunity to refine our use of f lank tumour models in rodents by developing a tumour risk classification scoring system. This system intends to simplify and standardise the decision-making process for personal licence holders (PILs) working across all our models; act as a training aid for new PILs; and support our responsibility to minimise pain, suffering, distress or lasting harm under ASPA.